50 sponsors and sites quantify what better patient recruitment is worth to them in the first independent ROI study in more than a decade
MALMO, Sweden and WILMINGTON, Del., Nov. 18, 2026 /PRNewswire-PRWeb/ -- Trialbee, the global leader in patient recruitment technology and AI, today shared new research from Everest Group showing that using a Patient Recruitment Platform (PRP) with pre-qualified referrals can speed enrollment by 15% and save sponsors US$1–3 million in a typical Phase 3 study. The report, Guided by Service, Powered by Technology, draws on structured surveys of 30 sponsors and 20 clinical research sites across the US, Europe, the UK and Latin America. Trialbee supported the research.
The headline results:
- Sponsors: 15% faster enrollment, about 1.8 months off a 12-month enrollment period, and up to US$3M saved per Phase 3 study of roughly 1,000 patients
- Cost per patient: about US$1,800 saved per enrolled patient, a 15% reduction in recruitment cost per patient
- Sites: about 25% faster to enrollment targets and US$15–20K in operational value per site, per study
- Forecasting: 77% of sponsors cite more accurate enrollment forecasting as a key benefit of central recruitment services
- Biggest opportunities: Pre-screening and patient outreach are sponsors' lowest-rated recruitment stage, prime for AI-powered improvement
"One of the things we were hoping this report could do is put data in the hands of sponsors and sites who are trying to justify the spend on a platform, because here you have a real payback in terms of time savings," said Matt Walz, CEO of Trialbee. "This is industry research you can use internally when you're looking to acquire a platform, and the report also lays out the metrics to track to make sure you're getting the gains you expected."
"We are beginning to see patient recruitment evolve from fragmented execution toward a more integrated model that combines service expertise with technology-enabled visibility," said Nisarg Shah, Vice President at Everest Group. "Central recruitment services can improve the quality and readiness of patient referrals, while PRPs provide the transparency needed to track progress, identify bottlenecks, and coordinate action. Together, these capabilities can reduce site burden, improve conversion, accelerate enrollment, and improve recruitment economics and return on investment. Based on insights from Everest Group's primary research, sponsors, CROs, and sites concur that this approach delivers both short-term and long-term ROI by making recruitment more predictable, efficient, and scalable across studies."
The report also includes a case study from the Indiana Clinical Trials Center and Nikki Mosley, Business Development Manager at Optima Dermatology, which reported 30% better referral-to-enrollment conversion after using Trialbee's secondary screening across three studies.
"Independent research matters because sponsors and sites deserve evidence they can trust, not vendor claims -- and that's coming from a marketing person," said Kris Sarajian, VP of Marketing at Trialbee. "We're grateful to Nisarg and the Everest Group team for their rigor. Most of all, we thank the 30 clinical operations and R&D leaders at biopharma companies and the 20 clinical research sites who shared their time, experience and insights. Their answers are what power these results."
Trialbee shared the full results and context of the report in a live webinar on Tuesday, November 17. The session walked through where the US$1–3M comes from, what sites gain, and what is slowing adoption, followed by live Q&A. The recording is now available on demand.
Download the report now or watch the webinar recording
To learn more about how Trialbee and the Honey Platform™ enable global patient recruitment results like these, visit www.trialbee.com.
About Trialbee
Trialbee is the global leader in patient recruitment technology and AI for clinical trials. Its leading Honey Platform™ unifies patient outreach, medical pre-qualification, site-patient communication, and reporting to improve referral quality, trial finder support, and last-mile site handoff across clinical programs and therapeutic areas. With more than 2.5 million patient journeys managed in Honey, Trialbee supports over 6,000 research sites across 50 countries and 66 languages – with a 91% repeat business rate with leading biopharmaceutical companies. Headquartered in Sweden and the United States, Trialbee is focused on advancing global patient recruitment to improve access to clinical research for all. Get started at www.trialbee.com.
Media Contact
Kristopher Sarajian, Trialbee, 46 101 963 260, [email protected], www.trialbee.com
SOURCE Trialbee


Share this article